A b s t r a c t
True myoepithelial tumors rarely are diagnosed in the breast. However, hyperplasia of the myoepithelial cells (MECs) often accompanies glandular hyperplasia (eg, sclerosing adenosis, papillomatosis) and can resemble benign myoepithelial neoplasms, ie, adenomyoepitheliomas (AMEs). A noninvasive growth pattern and a variable mixture of MECs and glandular elements characterizes AMEs. 1 The spindle shape of proliferating MECs and their ability to produce extracellular matrix may yield a histologic appearance that closely approximates that of metaplastic carcinomas (spindle cell and matrix-producing variants). Several earlier studies have demonstrated that metaplastic breast carcinomas may have immunohistochemical and ultrastructural characteristics consistent with myoepithelial differentiation, 2, 3 yet the issue of similarity between AME and metaplastic carcinoma has not been examined thoroughly. With the increased application of small-needle biopsies for the diagnosis of breast lesions, it is important to further explore the aforementioned similarities and to find significant differences. We compared the immunophenotypic characteristics and oncogene expression of normal breast MECs, benign myoepithelial breast tumors, and metaplastic breast carcinomas.
for these entities have been published. [4] [5] [6] The AMEs showed an admixture of proliferating spindle MECs and few epithelial-lined duct-like structures. In 2 cases, the AMEs were mostly solid, composed of polygonal or plasmacytoid cells containing few compressed epithelial-lined spaces. The mixed tumor (pleomorphic adenoma) showed an admixture of myoepithelial and epithelial cells in clusters or duct-like structures dispersed in a chondroid matrix. Spindle cell carcinomas were composed predominantly of elongated, cytokeratin-positive cells often showing a storiform growth pattern. Metaplastic matrix-producing carcinomas contained areas of chondroid differentiation admixed with areas of regular ductal carcinoma. One of the carcinomas showed a mixture of spindle cell and chondroid areas.
Immunohistochemical Analysis
Immunohistochemical staining was performed on formalin-fixed, paraffin-embedded sections by using an automatic immunostainer (DAKO, Carpinteria, CA) and a streptavidin-biotin-peroxidase complex technique (LSAB2 system, DAKO). Heat-induced epitope retrieval was performed in a Handy Steamer Plus (Black and Decker, Shelton, CT) in citrate buffer, pH 6.0 (DAKO) or EDTA (for maspin) for 20 minutes. The following primary antibodies were used: anti-estrogen receptor (ER; clone 1D5; dilution 1:400; DAKO), anti-progesterone receptor (PR; clone 1A6; dilution 1:80; DAKO), anti-androgen receptor (AR; clone AR441; dilution 1:100; DAKO), anti-cytokeratin AE1/3 (clone AE1/AE3; dilution 1:80; Signet, Dedham, MA), anti-HER-2/neu (rabbit polyclonal; dilution 1:3,200; DAKO), anti-S-100 (rabbit polyclonal; dilution 1:6,000; Ventana, Tucson, AZ), antivimentin (clone VIM3B4; dilution 1:400; DAKO), anti-p53 (clone DO-7; dilution 1:400; DAKO), antimaspin (clone G167-70; dilution 1:3,200; Pharmingen, San Diego, CA), anti-CD10 (clone 56C6; dilution 1:80; Neomarkers, Fremont, CA), anti-epithelial membrane antigen (EMA; clone E29; dilution 1:1,600; DAKO), anti-α-smooth muscle actin (SMA; clone 1A4; dilution 1:200; DAKO), and anti-smooth muscle myosin heavy chain (clone SMMS-1; dilution 1:400; DAKO). Negative controls were obtained by omitting the primary antibodies. Benign breast parenchyma adjacent to the tumor served as an internal positive control.
Double Immunohistochemical Analysis
For selected cases, double immunohistochemical staining was performed using the combinations of anti-SMA and anti-ER or anti-SMA and anti-EMA and the DAKO EnVision Doublestain System. The first and second primary antibodies were omitted independently in control sections. In addition, consecutive sections were stained individually with each of the antibodies.
Scoring
The results of immunostaining were graded on a 4-point scale (0-3) incorporating the intensity of staining and the percentage positive cells as follows: 0, no staining; 1+, weak, speckled staining that did not entirely cover the appropriate cellular compartment or uniform staining of the appropriate compartment seen in fewer than 10% of cells; 2+, complete but moderate staining of the appropriate compartment in more than 10% of cells; 3+, complete and strong staining in the appropriate cellular compartment seen in more than 10% of cells. ER, PR, AR, HER-2/neu, and p53 immunostains were considered positive for scores greater than 1. The remaining immunostains were designated as positive for scores greater than 0.
Results

Normal MECs
Normal MECs consistently expressed cytokeratin (AE1/3), SMA, myosin, S-100, CD10, maspin, and vimentin. They were negative for EMA, steroid receptors (ER, PR, and AR), p53, and HER-2/neu. Normal luminal cells did not express SMA, myosin, CD10, vimentin, or p53, yet they were strongly positive for EMA, AE1/3, and steroid receptors. Occasionally, weak expression of S-100, maspin, and HER-2/neu was observed for luminal cells.
Benign Myoepithelial Tumors
Results of immunostaining for the spindle cell component of benign myoepithelial tumors are summarized in ❚Table 1❚. The myoepithelial component of AMEs invariably showed immunoreactivity for cytokeratin, maspin, SMA, and S-100. The intensity and extent of SMA immunoreactivity, however, were decreased for some specimens compared with normal MECs. MECs in the benign myoepithelial tumors (AMEs) weakly and less frequently expressed CD10 (4/8 [50%] positive cases) and myosin (6/8 [75%]) ❚Figure 1❚. The majority of cases also were immunoreactive for vimentin and, surprisingly, EMA (5/8 [63%]). The myoepithelial component of the AMEs was consistently negative for HER-2/neu and p53 and sometimes showed weak reactivity for steroid receptors. Double immunohistochemical analysis showed that, contrary to normal MECs, luminal (EMA and steroid receptors) and myoepithelial markers (SMA, myosin, or CD10) often were expressed in the same cells ❚Image 1❚ and ❚Image 2❚. The myoepithelial component of the mixed tumor showed an immunophenotype similar to that of AMEs.
Metaplastic Carcinomas
The results of immunostaining for metaplastic carcinomas are given in ❚Table 2❚. Similar to the benign myoepithelial breast lesions, metaplastic carcinomas were positive for cytokeratin (AE1/3), vimentin, maspin, and S-100 and negative for HER-2/neu. Matrix-producing carcinomas frequently were positive for EMA. Double immunohistochemical analysis revealed that a population of tumor cells coexpressed EMA and α-SMA (Image 2). Compared with AMEs, spindle cell carcinomas were more often CD10+ and negative for myosin, while the concurrent absence of both SMA and myosin was more frequently observed in matrixproducing carcinomas (Figure 1 ). p53 was overexpressed in 4 (50%) of 8 metaplastic matrix-producing carcinomas and 1 (33%) of 3 metaplastic spindle cell carcinomas (Figure 1 ). Both types of metaplastic carcinomas were consistently negative for steroid receptors.
Discussion
Our results showed that benign myoepithelial breast lesions have an altered phenotype compared with normal MECs. This most often was manifested by the complete loss of CD10 expression in 5 (56%) of 9 cases and by the reduction in the intensity of expression of SMA and myosin. Furthermore, benign myoepithelial tumors unexpectedly expressed EMA and steroid receptors, which are classic luminal cell markers. CD10 is a neutral endopeptidase that cleaves peptide bonds on the amino side of hydrophobic acids. CD10 negatively modifies the interaction of a variety of physiologically active peptides with their receptors. 7 It inhibits cell migration, 8, 9 has a role in apoptosis, 10 and can influence signaling pathways important for growth regulation. 11 Decreased CD10 expression in human mammary MECs has been demonstrated after several passages in culture. 12 Our findings are in agreement with these experimental data and further suggest that the altered CD10 expression in benign myoepithelial lesions may contribute to neoplastic growth properties of myoepithelial tumors.
The myoepithelial component of AMEs often showed reduced levels of expression of SMA and occasionally absent myosin expression. Muscle markers were detected in the majority of previously studied cases of AME [13] [14] [15] [16] [17] and mixed tumors. 18 Adenomyoepithelioma  1/29  3  0  1  0  3  0  1  2  0  1  1  0  0  2/56  3  3  3  3  3  1  2  0  0  0  0  0  0  3/51  3  3  3  3  3  0  3  3  1  1  1  1  2  4/67  3  3  1  0  2  0  2  0  0  1  2  0  0  5/44  3  2  3  3  2  2  3  1  0  0  0  0  0  6/60  3  2  2  1  2  1  2  3  0  1  2  2  2  7/42  3  3  2  2  2  2  2  2  0  1  1  2  2  8/43  ND  2 reported decreased α-SMA expression in continuously passaged MECs. 12 No case in our series showed complete absence of both SMA and myosin. Some of the benign myoepithelial breast lesions coexpressed epithelial and myoepithelial markers in the spindlepolygonal cell component. These features may indicate an origin from a bipotent progenitor cell. Stingl et al 22 described a bipotent progenitor population in normal human mammary gland tissue with a capacity of generating cells with a luminal or myoepithelial phenotype. The same authors have shown that a small population of cells with a luminal or myoepithelial phenotype (EMA+/CD10+) appears after 72 hours of growth in vitro. The presence of steroid hormone receptors in some of the benign myoepithelial lesions included in our study further supports this notion. ER-positive AMEs 23 and mixed tumors of the breast 24, 25 have been reported. Those studies, however, could not confirm that neoplastic MECs expressed ER since biochemical assays were used. In 2 more recent immunohistochemical studies, 14, 20 ER was found in the ductal-epithelioid component of AMEs and mixed tumors, whereas the myoepithelial component was negative for ER. This is in contrast with our results and may be secondary to technical differences, including the absence of antigen retrieval, which may yield underestimation of weakly positive cells.
Metaplastic carcinomas of the breast were positive for cytokeratin, vimentin, S-100, and maspin, similar to normal MECs and benign myoepithelial lesions. Other authors found vimentin 2,3,26-29 and S-100 2,3 expression in these tumors, and our study confirmed such observations. However, it is important to recognize that vimentin expression has been observed frequently (33%-86% of cases) in carcinomas of the breast, in the absence of metaplastic features. 30 While 100% of matrix-producing carcinomas have been reported to express S-100, 3 spindle cell carcinomas and carcinosarcomas have exhibited weaker or, sometimes, absent S-100 immunoreactivity. 2, 28, 29 Cytokeratin expression in metaplastic breast carcinomas is variable. 2, 3, [26] [27] [28] [29] [31] [32] [33] Matrix-producing carcinomas reveal near absolute immunoreactivity for cytokeratin, 3, 27 while spindle cell carcinomas typically show reduced or absent cytokeratin expression. 2, 31, 33 In our series, we detected cytokeratin in all carcinomas studied. The previously reported cytokeratin negativity may reflect more sarcomatous features of those tumors, the focal nature of cytokeratin expression, or both. Further technical issues such as storage of archival material, different antibodies, and antigen-retrieval procedures could contribute to the differences.
In contrast with previous studies of nonmetaplastic carcinomas in which maspin immunoreactivity was found in only 25% of invasive ductal carcinomas, not otherwise specified type, 34 and 20% of tubular carcinomas, 35 we detected maspin in all tested metaplastic carcinomas. Maspin is a serine protease inhibitor, which is produced predominantly by breast MECs. 35, 36 It has been reported to inhibit invasion and motility of mammary carcinoma cells in vitro 37, 38 and tumor growth and metastasis in vivo. 38 It also has been shown to have an antiangiogenic effect. 39 The biological significance of maspin reactivity in metaplastic carcinomas is not clear. The strong maspin expression in matrix-producing breast carcinomas 2  3  0  0  3  1  0  3  0  0  0  0  0  5/39  3  2  0  0  2  0  3  2  0  3  0  0  0  6/51  3  2  0  2  3  0  2  2  0  3  0  0  0  7/62  3  2  ND  ND  3  0  3  0  ND  0  0  1  0  8/51  3  3  0  ND  ND  ND  2  3  0  ND  0  0  0  9/41  3  3  0  0  3  0  2  3  0  0  0  0  0  1 0 / 4 9  3  3  2  0  3  3  3  2  0  0  0  0  0  11/47  1  1  0  0  2  1  3  1  0  3  0  0  1  12/56  3  3  1  1  3  0  3  3  0  3  0  0  0 AR, androgen receptor; EMA, epithelial membrane antigen; ER, estrogen receptor; ND, not determined owing to loss of diagnostic material; PR, progesterone receptor; SMA, smooth muscle actin. * See the "Scoring" section in "Materials and Methods" for an explanation of the scoring system. † The tumor of this patient showed spindle cell and matrix-producing features.
may, at least in part, contribute to the reported more favorable prognosis compared with conventional carcinoma. 40 Contrary to the results for benign myoepithelial lesions, metaplastic carcinomas rarely expressed SMA or myosin, and there was only 1 case with simultaneous, weak expression of these antigens. There was a trend for higher expression of SMA in spindle cell carcinomas than in matrixproducing tumors. Variable expression of muscle markers has been reported. 2 27 reported weak EMA positivity in rare spindle cells and few epithelial cells in 4 of 8 metaplastic breast carcinomas with a "fibromatosis-like" component.
Metaplastic carcinomas in our study overexpressed p53 in 5 of 11 cases, which can help distinguish them from benign myoepithelial proliferations. Similarly Chhieng et al 40 observed p53 immunoreactivity in metaplastic components of 38% of carcinomas of the breast with osteocartilaginous heterologous elements.
We did not find HER-2/neu expression in benign myoepithelial lesions or metaplastic breast carcinomas, which shows that HER-2/neu cannot be used to differentiate those entities. Similarly Chhieng et al 40 and Sneige et al 33 showed that metaplastic matrix-producing and spindle cell carcinomas of the breast were HER-2/neu negative.
Benign myoepithelial tumors of the breast and metaplastic breast carcinomas demonstrate immunochemical profiles that are similar but not identical to those seen in MECs. This conclusion also is strongly supported by recently published preliminary results of complementary DNA microarray analysis that compared expression patterns of metaplastic carcinomas and benign myoepithelial tumors. 41 Because of this similar immunophenotype, the distinction between entities may be difficult, especially on a small biopsy specimen. Evaluation of classic myoepithelial markers has limited value in distinguishing benign from malignant tumors. Overexpression of p53 supports a diagnosis of metaplastic carcinoma; however, it is observed in fewer than 50% of the cases. Further studies are needed to reveal the oncogene abnormalities in the remaining portion of metaplastic carcinomas.
